GH Research (GHRS) Other Non Operating Income (2020 - 2026)
GH Research (GHRS) posted quarterly Other Non Operating Income of $140000.0 for Q4 2025, down 93.6% year-over-year from $2.2 million in Q4 2024, and up 156.68% quarter-over-quarter from -$247000.0 in Q3 2025.
Analysis
GH Research (GHRS) Other Non Operating Income (2020 - 2026) Analysis & Trends
GH Research's Other Non Operating Income history runs 5 years deep, the most recent figure standing at $140000.0 for Q4 2025.
- In Q4 2025, Other Non Operating Income fell 93.6% year-over-year to $140000.0; the TTM figure through Dec 2025 stood at $1.8 million (down 17.66% YoY), while the FY2025 annual figure was $1.8 million, down 17.66% from the prior year.
- Other Non Operating Income for Q4 2025 stood at $140000.0, up from -$247000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $7.1 million in Q2 2022, with the low at -$7.4 million in Q4 2022.
- The 5-year median for Other Non Operating Income is $937500.0 (2021), against an average of $1.2 million.
- Peak annual rise in Other Non Operating Income reached 25022.22% in 2022, while the deepest fall reached 393.04% in 2022.
- GH Research's Other Non Operating Income stood at $2.5 million in 2021, then tumbled by 393.04% to -$7.4 million in 2022, then soared by 172.88% to $5.4 million in 2023, then sank by 59.52% to $2.2 million in 2024, then plunged by 93.6% to $140000.0 in 2025.
- Business Quant data shows GHRS's Other Non Operating Income at $140000.0 in Q4 2025, -$247000.0 in Q3 2025, and $2.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | GH Research | 1.71 Bn | 1.35 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.31 Mn |
| Mar 31, 2026 | -2.33 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 5.42 Mn |
| Mar 31, 2025 | -642,000.00 |
| Dec 31, 2024 | 4.14 Mn |
| Sep 30, 2024 | 507,000.00 |
| Jun 30, 2024 | 2.84 Mn |
| Mar 31, 2024 | 3.86 Mn |
| Dec 31, 2023 | -113,000.00 |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | -518,000.00 |
| Dec 31, 2022 | -7.41 Mn |
| Sep 30, 2022 | 6.19 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | 2.24 Mn |
| Dec 31, 2021 | 2.52 Mn |
| Sep 30, 2021 | 2.83 Mn |